Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SHR-2173 in generalized myasthenia gravis
CTR20262007Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- May 2026
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-2173 in myasthenia gravis (MG), sponsored by Hengrui Therapeutics. Started May 2026; status: active.
02
Drugs
SHR-2173
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20262007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262007.